Japanese small-cap firms report broad margin expansion and strong earnings gains, with some trading at attractive valuations.
Pfizer sues Novo Nordisk to block its $8.5-$9B bid for Metsera, alleging antitrust violations and a 'kill' strategy to preserve dominance in GLP-1 obesity drugs.
FDA updates biosimilars guidance to streamline approvals and boost competition, aiming to cut regulatory barriers and speed lower-cost options to market.
Japanese small-cap firms report broad margin expansion and strong earnings gains, with some trading at attractive valuations.
Pfizer sues Novo Nordisk to block its $8.5-$9B bid for Metsera, alleging antitrust violations and a 'kill' strategy to preserve dominance in GLP-1 obesity drugs.
FDA updates biosimilars guidance to streamline approvals and boost competition, aiming to cut regulatory barriers and speed lower-cost options to market.